Clinical Value and Molecular Function of Circulating MicroRNAs in Endometrial Cancer Regulation: A Systematic Review.
biomarkers
circulating
endometrial cancer
miR
miR-150-5p
miR-27a
miR-29b
miRNA
microRNA
plasma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
03 06 2022
03 06 2022
Historique:
received:
14
04
2022
revised:
30
05
2022
accepted:
01
06
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
This systematic review of literature highlights the different microRNAs circulating in the serum or plasma of endometrial cancer patients and their association with clinical and prognostic characteristics in endometrial cancer. This study also investigates the molecular functions of these circulating microRNAs. According to this systematic review, a total of 33 individual circulating miRs (-9, -15b, -20b-5p, -21, -27a, -29b, -30a-5p, -92a, -99a, -100, -135b, -141, -142-3p, -143-3p, -146a-5p, -150-5p, -151a-5p, -186, -195-5p, -199b, -200a, -203, -204, -205, -222, -223, -301b, -423-3p, -449, -484, -887-5p, -1228, and -1290) and 6 different panels of miRs ("miR-222/miR-223/miR-186/miR-204", "miR-142-3p/miR-146a-5p/miR-151a-5p", "miR-143-3p/miR-195-5p/miR-20b-5p/miR-204-5p/miR-423-3p/miR-484", "mir-9/miR-1229", "miR-9/miR-92a", and "miR-99a/miR-199b") had a significant expression variation in EC patients compared to healthy patients. Also, seven individual circulating miRs (-9, -21, -27a, -29b, -99a, -142-3p, and -449a) had a significant expression variation according to EC prognostic factors such as the histological type and grade, tumor size, FIGO stage, lymph node involvement, and survival rates. One panel of circulating miRs ("-200b/-200c/-203/-449a") had a significant expression variation according to EC myometrial invasion. Further studies are needed to better understand their function and circulation.
Identifiants
pubmed: 35681531
pii: cells11111836
doi: 10.3390/cells11111836
pmc: PMC9180151
pii:
doi:
Substances chimiques
Circulating MicroRNA
0
MIRN186 microRNA, human
0
MIRN204 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Références
Oncotarget. 2016 Oct 18;7(42):68894-68908
pubmed: 27655698
Int J Clin Oncol. 2021 Aug;26(8):1431-1440
pubmed: 33835295
Int J Clin Exp Pathol. 2018 Feb 01;11(2):526-536
pubmed: 31938138
Expert Rev Mol Diagn. 2016 Dec;16(12):1315-1336
pubmed: 27817223
Cancers (Basel). 2021 Jul 06;13(14):
pubmed: 34298609
J Oncol. 2019 Dec 24;2019:7252013
pubmed: 31929798
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nucleic Acids Res. 2011 Sep 1;39(16):7223-33
pubmed: 21609964
Cancers (Basel). 2021 Mar 06;13(5):
pubmed: 33800944
Int J Oncol. 2017 Jun;50(6):1934-1946
pubmed: 28440489
Clin Lab. 2017 Oct 1;63(10):1675-1681
pubmed: 29035457
J Gynecol Oncol. 2021 Jul;32(4):e48
pubmed: 33908709
J Int Med Res. 2019 Aug;47(8):3803-3817
pubmed: 31187677
Gynecol Oncol. 2021 Aug;162(2):394-400
pubmed: 34127276
Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):746-754
pubmed: 29739748
Int J Clin Exp Med. 2015 Feb 15;8(2):3034-43
pubmed: 25932280
BMC Cancer. 2012 Aug 24;12:369
pubmed: 22920721
Int J Gynecol Cancer. 2021 Jun;31(6):868-874
pubmed: 33911004
Aging Cell. 2018 Feb;17(1):
pubmed: 29044988
RNA Biol. 2019 Dec;16(12):1733-1748
pubmed: 31425004
Neoplasma. 2015;62(4):509-20
pubmed: 25997972
Lancet. 2016 Mar 12;387(10023):1094-1108
pubmed: 26354523
Cancer Manag Res. 2020 Dec 31;12:13541-13552
pubmed: 33408524
J Exp Clin Cancer Res. 2018 Jul 13;37(1):147
pubmed: 30001734
Exp Ther Med. 2018 Jun;15(6):5205-5214
pubmed: 29904404
Nature. 2010 Aug 12;466(7308):835-40
pubmed: 20703300
PLoS One. 2020 Nov 11;15(11):e0242190
pubmed: 33175907
Int J Gynecol Cancer. 2016 Jul;26(6):1143-7
pubmed: 27177284
Am J Transl Res. 2019 Jun 15;11(6):3384-3397
pubmed: 31312352
Cancers (Basel). 2019 Jun 16;11(6):
pubmed: 31208108
Cancer Biomark. 2021;31(2):127-138
pubmed: 33896823
Gynecol Oncol. 2014 Mar;132(3):715-21
pubmed: 24491411
Biochem Med (Zagreb). 2021 Oct 15;31(3):030705
pubmed: 34658646
Oncol Lett. 2013 Jul;6(1):261-267
pubmed: 23946815
Cancer Biomark. 2020;27(2):225-242
pubmed: 32083575
Int J Cancer. 2013 Apr 1;132(7):1633-45
pubmed: 22987275
Mol Biol Rep. 2021 May;48(5):4351-4360
pubmed: 34076790
Int J Mol Sci. 2022 Jan 22;23(3):
pubmed: 35163161
PLoS One. 2015 Dec 10;10(12):e0143993
pubmed: 26657485
Exp Hematol Oncol. 2014 May 20;3:14
pubmed: 24910811
Microrna. 2018;7(2):148-154
pubmed: 29607782
J Obstet Gynaecol Res. 2016 Jun;42(6):612-7
pubmed: 27098274
Oncotarget. 2017 Apr 25;8(17):28471-28480
pubmed: 28212530
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Mol Cancer. 2021 Mar 29;20(1):57
pubmed: 33781255
Int J Gynecol Cancer. 2017 Mar;27(3):459-466
pubmed: 28129244
Annu Rev Biochem. 2019 Jun 20;88:487-514
pubmed: 31220978
Curr Oncol Rep. 2020 Jan 29;22(2):12
pubmed: 31997106
PLoS One. 2014 Oct 20;9(10):e110767
pubmed: 25329674
Mol Cancer. 2018 Oct 11;17(1):147
pubmed: 30309355
Nat Cell Biol. 2008 May;10(5):593-601
pubmed: 18376396
PLoS One. 2012;7(7):e41561
pubmed: 22859996
Nat Commun. 2021 Feb 11;12(1):952
pubmed: 33574259
Oncotarget. 2020 May 26;11(21):2010-2023
pubmed: 32523655
Oncogene. 2013 Feb 28;32(9):1164-72
pubmed: 22525276
J Cancer Res Clin Oncol. 2021 Mar;147(3):637-648
pubmed: 33511427
Biosci Rep. 2021 Jun 25;41(6):
pubmed: 34076696
Front Digit Health. 2020 Dec 11;2:573010
pubmed: 34713045
Am J Ther. 2016 Mar-Apr;23(2):e388-97
pubmed: 26618619
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Int J Mol Sci. 2018 Aug 07;19(8):
pubmed: 30087246
Oncol Rep. 2020 Jun;43(6):1897-1905
pubmed: 32236579
World J Gastroenterol. 2020 May 28;26(20):2570-2583
pubmed: 32523312
J Cancer. 2019 Jan 1;10(1):277-286
pubmed: 30662548
Future Oncol. 2018 Jun;14(14):1365-1376
pubmed: 29848072
Cancer Cell Int. 2019 Jul 15;19:181
pubmed: 31346316